• Home
  • >>>>>>>>>>>>> 2026 & BEYOND MASTER PLAN >>>>>>>>>>>>>>>>
  • Virtual Data Room (VDR) for Strategic Customized Slide Decks
  • TRAINABLE DATA ASSETS IN CORPORATE LEGACY & ORGANIZATION’s STRATEGIC MEMORY (2012 – 2025)
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Founder’s Vision
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder’s Bio
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2025 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • Blockchain Transactions Network Ecosystem
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • SOP Web STAT
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets
  • Audio English-Spanish: BioMed e-Series
  • Five Bilingual BioMed e-Series
  • Press Releases
  • Intangibles CIM
  • BioMed Audio Podcast Library @LPBI Group
  • Medical School Education: Use of LPBI Group’s Contents
  • ChatGPT + Wolfram PlugIn
  • Medicine with GPT-4 & ChatGPT
  • AGI, generativeAI, Grok, DeepSeek & Expert Models in Healthcare
  • Multimodal Healthcare Foundation Model
  • Cell Therapy in Regenerative Medicine, 2026 and Beyond
  • Contact Us

Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

Healthcare analytics, AI solutions for biological big data, providing an AI platform for the biotech, life sciences, medical and pharmaceutical industries, as well as for related technological approaches, i.e., curation and text analysis with machine learning and other activities related to AI applications to these industries.

Feeds:
Posts
Comments

Part 15 – Rosetta Stone Ontology & Domain-Specific Training Manual for Recursive Discovery Factories

Part 15 – Rosetta Stone Ontology & Domain-Specific Training Manual for

Recursive Discovery Factories

COM Part 15 introduces the proprietary Rosetta Stone Ontology, a structured translational framework that maps the full continuum from disease indications to therapeutics and corrective interventions. By integrating Journal Ontology, receptor mapping, and human-created training examples per medical specialty, it enables the creation of recursive discovery factories — autonomous, closed-loop systems that continuously learn and refine knowledge.

The Rosetta Stone gives Grok 4.20 (and future models) a decisive advantage: the ability to reason at the level of clinical mechanisms of action rather than relying solely on molecule-level combinatorics. Token usage analytics are embedded to ensure efficient, cost-effective recursive operation while maintaining high clinical relevance.

Update on 5/10/2026

Understanding the Agentic AI Hierarchy: From LLM to Full Agentic Systems

Visual (insert the image here):

[Insert Aqsa Zafar’s image: “Best LLMs Resources” showing the 4-level hierarchy]

Explanation Text:

The Agentic AI Hierarchy (as defined by leading AI practitioners)

Level Term Core Capability Limitation / Advancement
1 LLM Reads, writes, explains, answers No real-time data, can hallucinate, forgets context
2 RAG Retrieves external data and grounds responses Adds accuracy and reduces hallucination
3 AI Agent Thinks + acts using tools, APIs, code Executes tasks autonomously with short- and long-term memory
4 Agentic AI Multiple agents collaborating as a team Plans, coordinates, shares memory, pursues long-term goals

Why This Matters for AJAUS (COM Part 14)

AJAUS is deliberately designed as a Level 4 Agentic AI system — not a single LLM or simple agent, but a governed, multi-agent orchestration layer that:

  • Operates with human-in-the-loop oversight
  • Uses LPBI’s 9 GB high-provenance multimodal corpus as its trusted foundation
  • Connects to the Rosetta Stone Ontology (COM Part 15) for causal, clinically accurate reasoning and translational mapping
  • Ensures every action is traceable, auditable, and compliant

Cross-reference to COM Part 15: The Rosetta Stone Ontology provides the semantic and causal intelligence layer that turns raw agentic execution (AJAUS) into clinically trustworthy, high-provenance reasoning — the critical bridge between agent actions and real biomedical meaning.

Key Takeaway for LPBI We are not building another LLM or basic agent. We are building the trusted Agentic AI orchestration platform that the entire industry will need.

Update on 5/10/2026

Understanding the Agentic AI Hierarchy: From LLM to Full Agentic Systems

Explanation Text:

The Agentic AI Hierarchy (as defined by leading AI practitioners)

Level Term Core Capability Limitation / Advancement
1 LLM Reads, writes, explains, answers No real-time data, can hallucinate, forgets context
2 RAG Retrieves external data and grounds responses Adds accuracy and reduces hallucination
3 AI Agent Thinks + acts using tools, APIs, code Executes tasks autonomously with short- and long-term memory
4 Agentic AI Multiple agents collaborating as a team Plans, coordinates, shares memory, pursues long-term goals

SOURCE

https://www.linkedin.com/posts/aiforexecutives-official_llm-vs-rag-vs-ai-agent-vs-agentic-ai-%F0%9D%97%95%F0%9D%97%B2%F0%9D%97%B0%F0%9D%97%BC%F0%9D%97%BA%F0%9D%97%B2-activity-7440441956507336704-FBqI/

 

Why This Matters for AJAUS (COM Part 14)

AJAUS is deliberately designed as a Level 4 Agentic AI system — not a single LLM or simple agent, but a governed, multi-agent orchestration layer that:

  • Operates with human-in-the-loop oversight
  • Uses LPBI’s 9 GB high-provenance multimodal corpus as its trusted foundation
  • Connects to the Rosetta Stone Ontology (COM Part 15) for causal, clinically accurate reasoning and translational mapping
  • Ensures every action is traceable, auditable, and compliant

Cross-reference to COM Part 15: The Rosetta Stone Ontology provides the semantic and causal intelligence layer that turns raw agentic execution (AJAUS) into clinically trustworthy, high-provenance reasoning — the critical bridge between agent actions and real biomedical meaning.

Key Takeaway for LPBI We are not building another LLM or basic agent. We are building the trusted Agentic AI orchestration platform that the entire industry will need.

See.

  • COM – Part 15, Rosetta Stone Ontology Project & Design Document and AI Training Manual (Password Protected)

Share this:

  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Facebook (Opens in new window) Facebook
  • Print (Opens in new window) Print
  • Email a link to a friend (Opens in new window) Email

Like this:

Like Loading…

This page has the following sub pages.

  • COM – Part 15, Rosetta Stone Ontology Project & Design Document and AI Training Manual (Password Protected)

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 2,041 other subscribers
  • Recent Posts

    • FDA Moves Forward With Its Guidance Framework for Rare Disease Trials: 2026 August 3, 2026
    • Artificial Intelligence TRANSFORMS Medicine, Biotech and Healthcare, How? August 3, 2026
    • In Memoriam: Nobel Laureate J. Michael Bishop for discovery of Retroviral Oncogenes July 31, 2026
    • Companies Actively Engaging Artificial Intellegence for Drug Design: 2026 July 31, 2026
    • AI-Native Drug Discovery Landscape 2026 – How LPBI Group Differentiates in the New Era of Foundation Models July 19, 2026
    • In Memoriam: In Remembrance of Cancer Researchers who passed in 2026 July 13, 2026
    • Urgent Request for Action on Proposed Rule Affecting Federal Funding Grant Review July 7, 2026
    • 2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy Revolutionizing Treatments for Blood Cancers and Solid Tumors July 5, 2026
    • Protected: KOL on Competitive Dynamics: LPBI Group’s Founder’s Radar Screens on AI-in-Health, Life Sciences & BioPharma June 15, 2026
    • Tumor Infiltrating Lymphocytes (TIL) as a first of kind FDA approved immunotherapy for cancer June 12, 2026
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 sjwilliamspa

Powered by WordPress.com.

WPThemes.


Loading Comments...
%d